AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36055467 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 87
Study 36055467 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐1337 (all doses combined)
Number of subjects: 87
Study 33773189 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvacrol (1.2 mg/kg/day, n = 17)
Number of subjects: 33
Study 33773189 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 33
Study 34505292 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month psychological intervention in addition to standard physiological treatment
Number of subjects: 143
Study 34505292 — intervention group
Group type: COMPARATOR
Intervention: Standard physiological treatment
Number of subjects: 143
Study 33941155 — intervention group
Group type: EXPERIMENTAL
Intervention: MoM LDH THA
Number of subjects: 48
Study 33941155 — intervention group
Group type: COMPARATOR
Intervention: HR
Number of subjects: 48
Study 35861850 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese heart‐healthy diet
Number of subjects: 265
Study 35861850 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 265
Study 34543244 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose photodynamic therapy (PDT)
Number of subjects: 146
Study 34543244 — intervention group
Group type: COMPARATOR
Intervention: High-density subthreshold micropulse laser
Number of subjects: 146
Study 35543079 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage
Number of subjects: 97
Study 35543079 — intervention group
Group type: COMPARATOR
Intervention: Cryosurgery
Number of subjects: 97
Study 34822339 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational messages
Number of subjects: 636
Study 34822339 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional messages
Number of subjects: 636
Study 34822339 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple messages
Number of subjects: 636
Study 34822339 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 636
Study 34822339 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants (overall effect)
Number of subjects: 636
Study 34822339 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional messages (overall effect)
Number of subjects: 636
Study 34822339 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex messages (overall effect)
Number of subjects: 636
Study 34822339 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed messages (overall effect)
Number of subjects: 636
Study 35552364 — intervention group
Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol, 145 mg/m2, every 21 days
Number of subjects: 178
Study 35552364 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel)
Number of subjects: 178
Study 35552364 — intervention group
Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol
Number of subjects: 178
Study 35552364 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 178
Study 33583203 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized virtual reality
Number of subjects: 26
Study 33583203 — intervention group
Group type: COMPARATOR
Intervention: Non-personalized virtual reality
Number of subjects: 26
Study 33583203 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 26
Study 32707097 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced workspace configuration (ergonomically optimized)
Number of subjects: 14
Study 32707097 — intervention group
Group type: COMPARATOR
Intervention: Current workspace configuration (not ergonomically optimized)
Number of subjects: 14
Study 34009326 — intervention group
Group type: EXPERIMENTAL
Intervention: Alivecor® KardiaMobile ECG monitor usage
Number of subjects: 105
Study 35164488 — intervention group
Group type: EXPERIMENTAL
Intervention: U‐P‐needle group (ultrasound probe perpendicular to the needle)
Number of subjects: 59
Study 35164488 — intervention group
Group type: COMPARATOR
Intervention: U‐P‐artery group (ultrasound probe perpendicular to the artery)
Number of subjects: 59
Study 35164488 — intervention group
Group type: EXPERIMENTAL
Intervention: U‐P‐needle group
Number of subjects: 59
Study 35164488 — intervention group
Group type: COMPARATOR
Intervention: U‐P‐artery group
Number of subjects: 59
Study 32318871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus docetaxel
Number of subjects: 1253
Study 32318871 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 1253
Study 32087337 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2400 mg/day
Number of subjects: 0
Study 32087337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35418247 — intervention group
Group type: EXPERIMENTAL
Intervention: Values-affirmation intervention on medication adherence
Number of subjects: 825
Study 35418247 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial-resource strain
Number of subjects: 825
Study 35418247 — intervention group
Group type: EXPERIMENTAL
Intervention: Being uninsured
Number of subjects: 825
Study 33554750 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning + education intervention
Number of subjects: 102
Study 33554750 — intervention group
Group type: COMPARATOR
Intervention: Education-only condition
Number of subjects: 102
Study 33433171 — intervention group
Group type: EXPERIMENTAL
Intervention: ART (Antiretroviral Therapy)
Number of subjects: 3777
Study 33433171 — intervention group
Group type: COMPARATOR
Intervention: No ART
Number of subjects: 3777
Study 32963511 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised machine learning methods (linear classifiers and probabilistic classifiers)
Number of subjects: 30000
Study 33335847 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention (IBI) with only automated support by the system
Number of subjects: 153
Study 33335847 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention (IBI) with minimal human support
Number of subjects: 153
Study 33335847 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group
Number of subjects: 153
Study 33176757 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermic baths (HTB) twice weekly for 8 weeks (n = 22)
Number of subjects: 45
Study 33176757 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise program (PEP) of moderate intensity twice weekly for 8 weeks (n = 23)
Number of subjects: 45
Study 35237338 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-warming moxibustion combined with hyperbaric oxygen therapy (NWM + HBOT)
Number of subjects: 100
Study 35237338 — intervention group
Group type: COMPARATOR
Intervention: Needle-warming moxibustion (NWM)
Number of subjects: 100
Study 32335122 — intervention group
Group type: EXPERIMENTAL
Intervention: GRASP MRI with temporal resolution of 4.1 s
Number of subjects: 6
Study 32335122 — intervention group
Group type: EXPERIMENTAL
Intervention: GRASP MRI with semiquantitative analysis of time intensity curves
Number of subjects: 6
Study 32335122 — intervention group
Group type: EXPERIMENTAL
Intervention: GRASP MRI in presumed paragangliomas and schwannomas
Number of subjects: 6
Study 35863947 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mL bolus every 45 min
Number of subjects: 210
Study 35863947 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mL bolus every 45 min
Number of subjects: 210
Study 35863947 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mL bolus every 45 min
Number of subjects: 210
Study 34687398 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab + utomilumab + rituximab (arm A)
Number of subjects: 29
Study 34687398 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab + utomilumab + azacitidine (arm B)
Number of subjects: 29
Study 34687398 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab + bendamustine + rituximab (arm C)
Number of subjects: 29
Study 35262373 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Reality (MR) technology
Number of subjects: 92
Study 34238445 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg plus Ezetimibe 10 mg (ATO10/EZE10)
Number of subjects: 41
Study 34238445 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg alone (ATO40)
Number of subjects: 41
Study 35576957 — intervention group
Group type: EXPERIMENTAL
Intervention: tiragolumab plus atezolizumab
Number of subjects: 275
Study 35576957 — intervention group
Group type: COMPARATOR
Intervention: placebo plus atezolizumab
Number of subjects: 275
Study 34698750 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% Concord grape juice (CGJ) consumed with a meal
Number of subjects: 34
Study 34698750 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-free grape flavored drink with customary flavor essence (LP) consumed with a meal
Number of subjects: 34
Study 34698750 — intervention group
Group type: COMPARATOR
Intervention: Polyphenol-free grape flavored drink with reduced flavor essence (LPF) consumed with a meal
Number of subjects: 34
Study 34698750 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% Concord grape juice (CGJ) consumed alone
Number of subjects: 34
Study 34698750 — intervention group
Group type: COMPARATOR
Intervention: Polyphenol-free grape flavored drink without CG phenolics and reduced flavor essence (LPF) consumed alone
Number of subjects: 34
Study 34698750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive outcomes (assessed hourly through visual analog scales)
Number of subjects: 34
Study 32483186 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacy-based intervention for IAR
Number of subjects: 125
Study 32483186 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 125
Study 37257948 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity care with rapid uptitration of oral medications for heart failure
Number of subjects: 1078
Study 37257948 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1078
Study 32852632 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab subcutaneous (DARA SC)
Number of subjects: 522
Study 32852632 — intervention group
Group type: COMPARATOR
Intervention: Daratumumab intravenous (DARA IV)
Number of subjects: 522
Study 34242085 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 37
Study 34242085 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging-guided focused ultrasound surgery (MRgFUS)
Number of subjects: 37
Study 34242085 — intervention group
Group type: COMPARATOR
Intervention: UAE
Number of subjects: 37
Study 34242085 — intervention group
Group type: COMPARATOR
Intervention: MRgFUS
Number of subjects: 37
Study 33083852 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lozenges (Lactobacillus brevis CD2)
Number of subjects: 34
Study 33083852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 32159243 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentorship
Number of subjects: 60
Study 32159243 — intervention group
Group type: COMPARATOR
Intervention: Social support mentorship
Number of subjects: 60
Study 35809628 — intervention group
Group type: EXPERIMENTAL
Intervention: iCare PRO tonometer
Number of subjects: 101
Study 35809628 — intervention group
Group type: EXPERIMENTAL
Intervention: iCare IC200 tonometer
Number of subjects: 101
Study 35809628 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometer (GAT)
Number of subjects: 101
Study 35809628 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analog scale for comfort
Number of subjects: 101
Study 33514427 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose umbilical cord MSCs (200 × 10^6 cells, 3 infusions every other day for a total of 600 × 10^6 cells)
Number of subjects: 11
Study 33514427 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose placental MSCs (200 × 10^6 cells, 3 infusions every other day for a total of 600 × 10^6 cells)
Number of subjects: 11
Study 33514427 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose MSCs (both UC-MSCs and PL-MSCs)
Number of subjects: 11
Study 34196886 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco heating product (THP)
Number of subjects: 0
Study 34196886 — intervention group
Group type: COMPARATOR
Intervention: Control group (abstaining from cigarette smoking)
Number of subjects: 0
Study 34196886 — intervention group
Group type: COMPARATOR
Intervention: Continuing smokers (cigarette smoking)
Number of subjects: 0
Study 35054083 — intervention group
Group type: EXPERIMENTAL
Intervention: Early warning system (EWS) and hemodynamic algorithm
Number of subjects: 40
Study 35054083 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study 35020488 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop control (Tandem Control-IQ)
Number of subjects: 112
Study 33507929 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml/kg buccal 40% dextrose gel
Number of subjects: 2149
Study 33507929 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 2149
Study 32805715 — intervention group
Group type: EXPERIMENTAL
Intervention: Minds in Motion (MiM) The Maze
Number of subjects: 48
Study 32805715 — intervention group
Group type: COMPARATOR
Intervention: Yoga
Number of subjects: 48
Study 34018341 — intervention group
Group type: EXPERIMENTAL
Intervention: n-HAP
Number of subjects: 64
Study 34018341 — intervention group
Group type: EXPERIMENTAL
Intervention: NSF
Number of subjects: 64
Study 34018341 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo gel)
Number of subjects: 64
Study 34018341 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP
Number of subjects: 64
Study 36231933 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic intra-conditioning at 60% arterial occlusion pressure
Number of subjects: 34
Study 36231933 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic intra-conditioning at 80% arterial occlusion pressure
Number of subjects: 34
Study 36231933 — intervention group
Group type: COMPARATOR
Intervention: Without ischemic intra-conditioning
Number of subjects: 34
Study 34485529 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS+taping
Number of subjects: 46
Study 34485529 — intervention group
Group type: COMPARATOR
Intervention: TENS
Number of subjects: 46
Study 35954979 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise toolkit intervention (stick, theraband, sandbag, small ball) led by a physical therapist, 90 min per session, twice weekly for 3 months
Number of subjects: 90
Study 35954979 — intervention group
Group type: COMPARATOR
Intervention: Usual CCS activity program
Number of subjects: 90
Study 34803399 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus thoracic muscle plane block (TTPB) with general anesthesia (GA) and 15 mL of 0.25% bupivacaine
Number of subjects: 60
Study 34803399 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus thoracic muscle plane block (TTPB) with GA and 15 mL of 0.25% bupivacaine
Number of subjects: 60
Study 34803399 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA) with saline injection
Number of subjects: 60
Study 36055039 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model based on diffusion-weighted imaging (DWI) radiomics features
Number of subjects: 260
Study 33039316 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational pamphlet
Number of subjects: 137
Study 33039316 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 137
Study 32740972 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 6 mg once per day for 10 days
Number of subjects: 0
Study 32740972 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32444221 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength intervention
Number of subjects: 120
Study 32444221 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 35323067 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact RC/SC
Number of subjects: 12
Study 35323067 — intervention group
Group type: COMPARATOR
Intervention: Both structures sectioned
Number of subjects: 12
Study 35323067 — intervention group
Group type: EXPERIMENTAL
Intervention: RC sectioned first
Number of subjects: 12
Study 35323067 — intervention group
Group type: EXPERIMENTAL
Intervention: SC sectioned first
Number of subjects: 12
Study 35323067 — intervention group
Group type: EXPERIMENTAL
Intervention: RC repair
Number of subjects: 12
Study 35010916 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg twice daily)
Number of subjects: 101
Study 35010916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 33405284 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine-based cue planning
Number of subjects: 192
Study 33405284 — intervention group
Group type: COMPARATOR
Intervention: Time-based cue planning
Number of subjects: 192
Study 32980829 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (0.2%)
Number of subjects: 3
Study 32980829 — intervention group
Group type: COMPARATOR
Intervention: Chitosan (0.5%)
Number of subjects: 3
Study 32980829 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine - Chitosan combination
Number of subjects: 3
Study 36355920 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based CBT-I app
Number of subjects: 175
Study 36355920 — intervention group
Group type: COMPARATOR
Intervention: Sham app
Number of subjects: 175
Study 33914140 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime sleepiness
Number of subjects: 20806
Study 33287874 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual EEG features
Number of subjects: 364
Study 33287874 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual EEG features + clinical features
Number of subjects: 364
Study 33287874 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual EEG features for HIE patients
Number of subjects: 364
Study 33287874 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual EEG features for TBI patients
Number of subjects: 364
Study 33287874 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual EEG features for metabolic, inflammatory or infectious causes
Number of subjects: 364
Study 33287874 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual EEG features for stroke patients
Number of subjects: 364
Study 33440437 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided intratumoral radioactive phosphorus-32 (32P) implantation followed by six chemotherapy cycles
Number of subjects: 12
Study 33058473 — intervention group
Group type: EXPERIMENTAL
Intervention: OL‐HDF
Number of subjects: 97
Study 33386633 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation-focused leisure-time physical activity intervention
Number of subjects: 33
Study 32732620 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular neurostimulation
Number of subjects: 92
Study 32732620 — intervention group
Group type: COMPARATOR
Intervention: Sham control (placebo)
Number of subjects: 92
Study 32732620 — intervention group
Group type: EXPERIMENTAL
Intervention: High vagal efficiency treatment group
Number of subjects: 92
Study 35699170 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rivaroxaban
Number of subjects: 6564
Study 35699170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6564
Study 35699170 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 6564
Study 32536547 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02 malaria vaccine
Number of subjects: 0
Study 36100927 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOT (Hyperbaric Oxygen Treatment)
Number of subjects: 120
Study 36100927 — intervention group
Group type: COMPARATOR
Intervention: Standard trauma care
Number of subjects: 120
Study 32564365 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (bolus of 1.5 mg.kg−1, continuous infusion of 2 mg.kg−1.h−1 until end of surgery, then 1 mg.kg−1.h−1 for 1 hour in recovery)
Number of subjects: 176
Study 32564365 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (identical volumes and rates)
Number of subjects: 176
Study 32564365 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 176
Study 32772366 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive left pancreatectomy (MIS LP)
Number of subjects: 1610
Study 32772366 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic left pancreatectomy
Number of subjects: 1610
Study 34060209 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide (initial 3 mg dose)
Number of subjects: 782
Study 32940243 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed public health message promoting the benefits of screening
Number of subjects: 0
Study 32940243 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment attributes (effectiveness and out-of-pocket cost)
Number of subjects: 0
Study 32940243 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentive for screening
Number of subjects: 0
Study 32940243 — intervention group
Group type: EXPERIMENTAL
Intervention: Correcting misconceptions about screen-detected cancer prognosis or providing greater financial protection
Number of subjects: 0
Study 34153592 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous patent foramen ovale closure
Number of subjects: 0
Study 34153592 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study 32544350 — intervention group
Group type: COMPARATOR
Intervention: Cytokines (IL-6, IL-8, IL-10) levels in patients with benign and malignant neoplasia
Number of subjects: 0
Study 32544350 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokines (IL-6, IL-8, IL-10) levels in ovarian cancer patients
Number of subjects: 0
Study 32544350 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (post-surgery)
Number of subjects: 0
Study 32544350 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-off values for IL-6, IL-8, and IL-10
Number of subjects: 0
Study 34534404 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour at 41 weeks of gestation
Number of subjects: 1373
Study 34534404 — intervention group
Group type: COMPARATOR
Intervention: Expectant management until 42 weeks of gestation
Number of subjects: 1373
Study 33187116 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive–behavioral conference call intervention (CBCC)
Number of subjects: 219